Xcout Intel
Aurin Biotech Inc. competitors & alternatives
The 12 closest competitors and alternatives to Aurin Biotech Inc. among biotechnology companies — ranked by similarity to what Aurin Biotech Inc. actually does, not by market-cap band.
Subscribe to see Aurin Biotech Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Aurin Biotech Inc.
Aurion Biotech Inc. develops regenerative cell therapies for ophthalmology, focusing on treatments for corneal endothelial disease and vision loss. Its lead product, AURN001, is a combination therapy utilizing human corneal endothelial cells designed to restore corneal clarity and provide a minimally invasive alternative to traditional donor tissue transplantation. The company serves patients suffering from blindness and provides advanced treatment options for ophthalmologists.
Aurin Biotech Inc. at a glance
Aurin Biotech Inc. is a biotechnology company headquartered in Canada. Its most recent funding round raised $795,029 in May 2018. Xcout tracks 33 named people at Aurin Biotech Inc., including Jeannette Bankes (President CEO of GE HealthCare’s Patient Care Solutions segment).
Aurin Biotech Inc. leadership
- Jeannette BankesPresident CEO of GE HealthCare’s Patient Care Solutions segment
- Andrew Torres, PhDChief Manufacturing Officer
- Edward J. Holland, MDChief Medical Officer
- Sterling ChungChief Regulatory & Quality Officer
- ARNAUD LACOSTECEO and Chief Scientific Officer
- Eris P. JordanChief Development Officer
27 more named people on record for Aurin Biotech Inc., with roles, board committees and tenure — see the full roster →
Aurin Biotech Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $795,029 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Aurin Biotech Inc. competitors
Ranked by semantic similarity — how close each company is to Aurin Biotech Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Biotech
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.
Similar biotechnology company
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Similar biotechnology company
Autonomy Bio Inc. is a biotechnology company focused on developing human aging therapeutics aimed at extending healthspan and mitigating age-related decline. The company targets individuals seeking to maintain health and independence as they age.
Biotech
Clearside Biomedical, Inc. operates as a biopharmaceutical company, specializing in novel approaches to administer therapies to the posterior region of the eye via the suprachoroidal space. Its market-approved product, XIPERE, is an injectable suspension containing triamcinolone acetonide, utilized to manage macular edema associated with uveitis. Additionally, the firm is progressing CLS-AX, an axitinib injectable suspension intended for suprachoroidal injection, having concluded its Phase 2 clinical trial for the treatment of wet age-related macular degeneration (AMD). Strategic collaborations are in place with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Founded in 2011 and headquartered in Alpharetta, Georgia, Clearside Biomedical regrettably initiated Chapter 11 reorganization proceedings by filing a voluntary petition with the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025.
Similar biotechnology company
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Similar biotechnology company
Broadwing Bio is a biotechnology company that develops antibody-based therapies to treat major causes of adult vision loss, specifically focusing on Geographic Atrophy and Glaucoma. The company utilizes genetics-driven insights to target ocular diseases and preserve vision for patients.
Similar biotechnology company
CellCure Neurosciences is an Israeli biotechnology company developing cell-based therapies derived from pluripotent stem cells, notably retinal pigment epithelium cells for treating retinal diseases such as geographic atrophy associated with dry age-related macular degeneration. Its intended customers and beneficiaries include ophthalmology researchers, clinical partners, and patients with degenerative retinal conditions.
Similar biotechnology company
Autobahn Therapeutics is a biotechnology company headquartered in San Diego, California, focused on developing restorative treatments in the medical sector.
Biotech
Adverum Biotechnologies is a clinical-stage biotechnology research company headquartered in Redwood City, California. The company focuses on developing novel gene therapies designed to redefine ocular care and treat severe eye diseases.
Similar biotechnology company
Neurotech Pharmaceuticals is a biotechnology company that develops transformative therapies for chronic eye diseases, utilizing its proprietary Encapsulated Cell Therapy platform. The company serves patients with conditions such as Macular Telangiectasia Type 2 by providing advanced treatments designed to protect against progressive vision loss.
Biotech
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a personalized gene-corrected cell therapy that has progressed to Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. The company's pipeline also encompasses several other programs: ABO-102, an adeno-associated virus (AAV)-based gene therapy designed for Sanfilippo syndrome type A; ABO-201, aimed at CLN3 disease; ABO-401, targeting cystic fibrosis; and ABO-50X, intended for genetic eye disorders. Additionally, Abeona actively advances AAV-based gene therapies through its proprietary AIM vector platform. Incorporated in 1974, the firm was initially named PlasmaTech Biopharmaceuticals, Inc. before officially adopting the name Abeona Therapeutics Inc. in June 2015. The company's corporate base is situated in New York, New York.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Aurin Biotech Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Aurin Biotech Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →